Mission

ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases.

History
ZymoGenetics, Inc. was founded in June 1981 by three noted university professors: Earl W. Davie, Professor of Biochemistry at the University of Washington; Benjamin D. Hall, Professor of Genetics at the University of Washington; and the late Michael Smith, Professor of Biochemistry at the University of British Columbia and 1993 Nobel Laureate. In 1988, Novo Nordisk acquired the company and for the next twelve years ZymoGenetics operated as the U.S. research arm of Novo Nordisk. In November of 2000, ZymoGenetics became an independent company, and in February of 2002, ZymoGenetics completed its initial public offering, raising $120M.

Chief Executive Officer: Bruce L.A. Carter, Ph.D.

President: Douglas E. Williams, Ph.D.

Cash Position: The Company's cash, cash equivalents and short-term investments totaled approximately $81 million (as of 09/30/2008)

2007 Revenues: $38.5 million

Number of Shares Outstanding: approx. 68.7 million (as of 09/30/2008)

Stock Exchange Listing: NASDAQ: ZGEN

Number of Employees: 528 (as of 09/30/2008)

Discovery efforts: ZymoGenetics has a growing pipeline of potential product candidates that includes proteins, antibodies and antibody-like molecules

Marketed Product

RECOTHROM® Thrombin, topical (Recombinant) approved by U.S. FDA for use as a topical hemostat

Product Candidates in Clinical Trials